"当センターは宮城県におけるがん治療の拠点として、高度な診療機能を確保しています。 「患者さんの視点に立ち、良質かつ先進的医療を提供し、がん専門病院としての使命を果たす」 という基本理念のもとに医療を行っております。"

During the past decade, Miyagi Cancer Center conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Miyagi Cancer Center" #1 sponsor was "Chugai Pharmaceutical" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Daiichi Sankyo Co., Ltd." with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Miyagi Cancer Center" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Miyagi Cancer Center" are "Carcinoma, Non-Small-Cell Lung" (2 trials), "Colorectal Cancer" (2 trials), "Head and Neck Cancer" (2 trials), "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)" (1 trials) and "Extensive Disease Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Miyagi Cancer Center" in a lesser frequency.

Most popular intervention types in "Miyagi Cancer Center" are "Drug" (14 trials), "Combination Product" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Docetaxel" (3 trials), "Avelumab" (2 trials), "Cisplatin" (2 trials) and "UFT adjuvant chemotherapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Miyagi Cancer Center" are 16 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Miyagi Cancer Center". undefined are not yet recruiting, 2 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Miyagi Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Miyagi Cancer Center, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".